What it sells
Creating new protein-based drugs at scale
Business model breakdown
Buyer: who owns the budget?
UnverifiedBiotech and pharma program leads who commission a manufacturing programme.
Trigger: what makes them buy now?
AI can design drugs faster than traditional manufacturing can make them; antimicrobial resistance needs pathogen-specific phages in days.
Workflow: what inputs become what output?
Computational design coupled with high-throughput cell-free wet-lab validation, then scale-up from picoliter droplets to GMP volumes on one platform.
Economics: what it saves and how it charges
Claims over 90% gross margin at $1-2k COGS versus $5-10k traditional; grant funding (SPRIND challenge, EUR 250,000 TUM award).
Distribution: how it reaches customers
Programme-based engagements: "Discuss a programme" contact.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2023 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.